drugset / Trial / NCT00922129
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the role and effectiveness of conversion to sirolimus versus CNI reduction in renal transplant patients with prostate cancer.
Timeline
- Start
- 2009-09
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 3 mg/kg | Oral |
| Comparator | Cyclosporine | Peptide | 4 mg/kg | Oral |
| Subject | Sirolimus | Small molecule | 5 mg | Oral |
| Comparator | Tacrolimus | Small molecule | 0.038 mg/kg | Oral |
| Comparator | Tacrolimus | Small molecule | 0.045 mg/kg | Oral |